Little is known of the causes of childhood brain tumors (CBT). The aims of this study were to investigate whether extremes of birth weight were associated with increased risk of CBT and whether maternal preconceptional folic acid supplementation or breastfeeding reduced the risk. In addition, other maternal characteristics and birth related factors were also investigated. We pooled data from two French national population-based case-control studies with similar designs conducted in 2003-2004 and 2010-2011. The mothers of 510 CBT cases (directly recruited from the national childhood cancer register) and 3,102 controls aged under 15 years, frequency matched by age and gender did a telephone interview, which focussed on demographic and perinatal characteristics, and maternal life style habits and reproductive history. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression, adjusted for age, sex, study of origin and relevant confounders. No association was found between CBT and birth weight or fetal growth. The use of preconceptional folic acid supplementation was rare (5.3% in cases and 7.8% in controls) and the OR was 0.8 (95% CI 0.5, 1.4). There was no association with breastfeeding, even prolonged (six months or more; OR 1.0, 95% CI 0.8, 1.4). Neither was there any association between CBT and other investigated factors (maternal body mass index, gestational weight gain, congenital abnormality, maternal reproductive history or use of fertility treatments. Although large, this study was underpowered for subtype analyses. Pooling data with other population-based studies may provide further insight into findings by CBT subtypes.
Childhood brain tumours (CBT) are the most common solid tumours in childhood in France as in other industrial countries. 1 The early age of diagnosis, especially for ependymoma, suggests a role for prenatal, perinatal or genetic factors. The only established risk factors are genetic syndromes such as neurofibromatosis (NF) Types 1 and 2 and high dose radiation to the head, although factors which may increase risk of CBT include abnormal fetal growth and other birth and maternal characteristics while periconceptional folic acid may potentially be protective. 2 The association between extremes of birth weight and CBT has been frequently investigated. Of nine papers published since 2010, [3] [4] [5] [6] [7] [8] [9] [10] [11] the majority reported a positive association with higher birth weight, for either all CBT combined or at least one subtype, 4-10 most commonly astrocytoma 4, 5, 8, 9 and one with lower birth weight. 8 However, this apparent weight of evidence includes case populations from similar geographical areas with at least some overlapping diagnosis years with three from Scandinivia, [8] [9] [10] three from California, 4, 5, 7 and two from Texas. 5, 6 The findings in relation to fetal growth (rather than birth weight per se) are more heterogeneous, with only three of these studies reporting an association with being large-forgestational age (LGA) 7, 8, 10 and two with being small-forgestational age (SGA). 4, 8 By contrast an Australian study found no association with either birth weight per se, or with another measure of fetal growth, the percentage of optimum birth weight (POBW), which in addition to sex, birth weight and gestational age, also took into account maternal parity and height. 11 However, they did report an association with a possibly related factor, namely a measure of inappropriate maternal gestational weight gain (GWG). 11 Several studies have reported protective associations between folic acid supplementation around conception 12, 13 and CBT, or multivitamin use around this time and medulloblastoma/primitive neuroectodermal tumours (PNET) 14, 15 but not with astrocytoma. 15 By contrast, a recent Norwegian study reported no association with folic acid during the combined time periods of before and/or during pregnancy. 16 It is plausible that periconceptional folic acid could be a protective factor for CBT. Low folate levels at this time may be associated with increased DNA methylation, thereby suppressing expression of genes, such as OTX2, which are implicated in neural crest development in the critical first week following fertilisation. 17 While there may be a protective association between breastfeeding and childhood cancer overall, 18 acute lymphoblastic leukemia, 18, 19 and neuroblastoma, 18, 20 previous publications 19 , [21] [22] [23] [24] have found no such association with CBT. However, as other factors related to the early priming of the immune system, that is, allergy 25 and asthma, [25] [26] [27] have been associated with decreased risk, a protective association is still plausible. Finally, there is inconsistent findings in regards to other birth and maternal factors, such as the birth defects 4, 28, 29 and use of fertility treatments. [30] [31] [32] The ESCALE study has previously reported no associations with birth related factors, including birth weight, breastfeeding and the risk of CBT, but a positive association between a maternal history of miscarriage, particularly glial cell tumours. 33 The same research team has now conducted a similar study named ESTELLE, to complement the previous study and increase statistical power. To verify the earlier findings, we have now pooled data from both studies. In this paper, our aim was to investigate whether factors related to conception, pregnancy and birth were related to the risk of CBT. Specifically, we aimed to investigate the following hypotheses: the risk of CBT would be increased by high fetal growth but decreased by the use of preconceptional folic acid supplements and breastfeeding. We also aimed to investigate whether there was any association with other prenatal and perinatal factors such as maternal reproductive history and congenital abnormalities. In addition, we aimed to stratify our analyses by the main histological subtypes.
Methods
The ESCALE and ESTELLE were both national, populationbased case-control studies which aimed to investigate the role of environmental, infectious and genetic factors in childhood cancers (leukaemia, lymphoma, neuroblastoma and CBT [both studies], nephroblastoma and hepatoblastoma [ESTELLE only]), and which were conducted with the support of the Soci et e Française de lutte contre les Cancers et leuc emies de l'Enfant et de l'adolescent. The study designs of both studies have been previously described in detail elsewhere. 33, 34 This article focusses on CBT.
What's new?
In the search for causes of childhood brain tumors (CBTs), birth weight, fetal growth and maternal behaviors have attracted significant interest. Despite extensive study, however, associations between those factors and CBTs remain unclear. This investigation of 510 CBT cases and over 3,000 controls from two French studies yields no evidence of an association between fetal growth and CBT risk. There also was little indication that maternal preconceptional folic acid supplementation or breastfeeding protect against CBTs. The findings highlight the importance of replicating analyses in different populations and the need for international consortiums to make full use of available data.
Study population
The cases in both studies were directly identified using the French National Registry of Childhood Cancers (Registre National des Cancers de l'Enfant, RNCE). The definition of a case was any child diagnosed with a malignant tumour in diagnostic group III according to the International Classification of Childhood Cancer Third edition (ICCC-3). 35 The RNCE uses microscopic reports to classify histological subtypes of CBT for about 85% of the CBT cases with the remainder being classified according to their clinical or imaging diagnosis. In the ESCALE study, only malignant tumours were included while for the ESTELLE study, the nonmalignant tumour cases were included as well. Eligible cases were children aged under 15 years diagnosed in [2003] [2004] (ESCALE) and 2010-2011 (ESTELLE), and who were resident in mainland France at the time of diagnosis. Ineligible case children were those who were receiving palliative care and those who died (n 5 79) and those whose biological mother were not available for interview (n 5 9), were nonFrench speaking (n 5 21) or who had serious psycho-social problems (n 5 7; Supporting Information Fig. 1 ). The study protocols complied with the French regulations relating to databases and ethics and the pertinent ethical approvals were obtained.
The methods used to recruit the controls have been previously described. 34 Briefly, controls were frequency matched by sex and age, using quotas to ensure the samples were representative of the general French population of families with children aged under 15 years and to ensure that there would be at least one control per cancer case in ESCALE and at least one control per case by ICCC-3 diagnostic group in ESTELLE. Like cases, controls were ineligible if the mother was not available for interview or non-French speaking. The control recruitment processes are shown in Supporting Information Figure 2 . The main difference by study was that for ESCALE, a random sample of existing telephone numbers was drawn from the telephone directory, and then modified by adding one to the final digit of the original sample, thus being from the same geographical area but which included some unlisted numbers, while in ESTELLE a sample of randomly generated telephone numbers was used.
Data collection
Data were collected using computer assisted interviews for both studies. Before commencing the interview, mothers were asked to have the child's carnet de sant e (personal health record) with them to aid recall. Both interviews collected data about the following: socio-demographic information, birth characteristics (such birth weight, birth order, gestational age and presence of a congenital malformation), index pregnancy (maternal age at child's birth, use of vitamin (including folic acid) and/or mineral supplement use before conception and during pregnancy, plurality, mode of delivery and smoking during pregnancy), and breastfeeding, including duration and previous reproductive history. Additional questions were asked about type(s) of congenital malformation, and whether they had difficulty in becoming pregnant, which was defined as taking more than a year to conceive and/or the need to consult a doctor and/or the need for either parent to have any fertility treatment. If yes, details were collected about type(s) of treatment. The script used for the ESCALE study was modified and enriched for the ESTELLE study with more detailed questions on some topics (maternal prepregnancy anthropometrics and gestational weight gain, more details information about previous pregnancy loss, and product name of vitamin and/or mineral supplement(s)).
Data management
Birth weights per se were categorised into three groups, <2,500, 2,500-3,999 g and 4,000 g or more. In addition, fetal growth was assessed using two methods. First, birth weight for gestational age were calculated using population and sexspecific formulas developed by the Association des Utilisateurs de Dossiers Informatis es en P ediatrie Obst etrique et Gyn ecologie (Association of Computerized Record Users in Pediatrics, Obstetrics and Gynecology; AUDiPOG). 36 SGA and LGA infants were defined as those below the 10th percentile and above the 90th percentile of weight, respectively. Second, the same formula as reported in the Australian casecontrol study 11 to calculate the POBW was applied using ESTELLE data only, as maternal height was not collected in the ESCALE study.
Maternal Body Mass Index (BMI) just before pregnancy was calculated in the ESTELLE study and categorized as underweight (<18.5 kg/m . Appropriateness of maternal gestational gain was categorised using the 2009 Institute of Medicine Guidelines criteria, 37 as done in the Australian study which found an increased risk with extremes. 11 That is, appropriate weight gains were defined according to baseline BMI of the women (12.5-18 kg for underweight, 11.5-16 kg for normal weight, 7-11.5 kg for overweight and 5-9 kg for obese women). Weight gains under or over these levels were defined as inadequate or excessive, respectively.
Congenital malformations were coded according to the 5-digit British Paediatric Association ICD-9 system as used in the Western Australian Register of Development Anomalies. 38 Breastfeeding was defined as the child having been breastfed for at least three days (similar to other studies 19, 21 ) and ever breastfed children were categorised into three groups (less than three months, at least three months, but less than six months and six months or more).
The use of any vitamin, mineral or folic acid supplements was coded as binary (ever/never) for the three months before pregnancy and any time during the pregnancy. For folic acid, a more specific classification was also used, based on the product name. If the mother named a product containing folic acid, we defined this as "substantiated" folic acid and "unsubstantiated" if she reported taking folic acid without giving a valid product name. For those who took substantiated folic acid, the product name was used to estimate the dose of folic acid supplementation (< or 400 mg/day), based on the assumption that the product was taken once a day. While the first recommendations about periconceptional folic acid in France were released in 1997 and 2000, its active promotion among physicians only started in 2004. 39 To enable us to investigate whether the folic acid findings changed based on this promotion, the children's birth years were categorised into three groups, (1995-1999, 2000-2005, 2006-2011) , to clearly identify which children were born before, around or after these dates.
As well as a binary variable for any fertility treatments, the types of treatments were categorized as in vitro fertilisation, the use of ovulation stimulating treatment, and artificial insemination.
Statistical analyses
In addition to exploring differences by case-control status, we explored the differences of the key demographic characteristics and selected birth factors by study among the controls since the characteristics and behaviours of women giving birth in France had changed between the study time periods. 40 Unconditional logistic regression (SAS version 9.3, SAS Institute Inc, Cary, NC) was used to estimate pooled ORs and 95% confidence intervals (CIs) for case-control and control by study analyses while polytomous logistic regression was used to estimate ORs for CBT subtypes. Odds ratios for birth weight, birth order and gestational age were modelled in the same multivariate model. The breastfeeding analyses were restricted to children age one year or older to properly assess whether there was an association with duration of breastfeeding. The analyses for POBW, maternal BMI, GWG and some factors related to maternal reproductive history were restricted to the ESTELLE study as these data were not collected in the ESCALE study. POBW was modelled as a continuous variable after preliminary modelling using fractional polynomial modelling indicated that this was the most appropriate model, with the OR calculated for one standard deviation difference. These models excluded children born <30 weeks gestation, those resulting from a multiple birth and those with a POBW >200 (which were considered to be unreliable). Models of GWG excluded women who had preterm and/or multiple birth as we could not define appropriate gestation weight gain for them. The analyses about the use of any vitamin, mineral or folic acid supplements were restricted to the ESTELLE study as the use of preconceptional folic acid supplements was extremely rare in the ESCALE study (overall prevalence 0.5%, results not tabulated).
All models included the frequency-matching factors of age (in one year age categories) sex and for analyses with data from both studies, a variable denoting study of origin. Between study heterogeneity was assessed by the use of an interaction term between study and the factor of interest. Since generally there was no interaction between studies and the findings by individual studies were similar, only the results for the pooled analyses are presented. The following variables were considered to a priori to be potential confounders: birth order, birth period, multiple pregnancy, parental age groups and urban status of the municipality of residence. The final covariates in each model are listed in the footnotes of the Tables. Effect modification by the child's age of diagnosis (under 5 years of age, 5 years and older) or birth year were explored by doing stratified analyses and by fitting interaction terms. Effect modification was similarly assessed for maternal smoking during pregnancy in the analyses of fetal growth. Finally, the analyses of fetal growth and vitamin use were also repeated excluding children born as a result of a multiple birth or the use of fertility treatments to control for potential confounding by these.
Since controls were recruited from a sample of landline telephone numbers, sensitivity analyses were done excluding cases whose families did not have a landline using the ESTELLE data (the only study for which these data were collected). Sensitivity analyses were also done excluding cases with nonmalignant tumours, and children with congenital anomalies or NF.
Results
Overall, the pooled analyses included 510 cases (87.8% of those eligible; 209 from ESCALE and 301 from ESTELLE; Supporting Information Fig. 1 ) and 3,102 controls (77.1% of eligible controls; 1,681 from ESCALE and 1,421 from ESTELLE; Supporting Information Fig. 2 ). Using the ICCC-3 histological subtype classifications, there were 64 ependymomas, 120 astrocytomas, 206 embryonal tumours and 109 other gliomas with 11 other specified (8) or unspecified neoplasms (3) . The distribution by study, age at diagnosis and malignancy status are shown in Supporting Information Table 1 . In total, 437 (85.7%) of the tumours were malignant and 73 were nonmalignant, the majority of which were astrocytomas (51) or other gliomas (20) .
Heterogeneity between studies
Because of differences in the study designs, there was a difference in the age distributions between the ESTELLE and ESCALE controls (Table 1) . They also more often lived in rural or less populated municipalities. ESTELLE mothers were older and better educated than ESCALE mothers (Table  1) and were more likely to have taken folic acid (p 5 <0.001), have used fertility treatments prior to the index pregnancy (p 5 0.02) and to have breastfed their children (p 5 <0.001; Results not tabulated).
Case-control comparability
The cases and controls differed by age (Table 1) as the control sampling was performed to enable analyses of multiple cancer diagnoses, the control group had the same age Cancer Epidemiology distribution as the whole ESCALE and ESTELLE case samples, but there were at least four controls for every case in each age. There were slightly more multiple births among the cases than among the controls. In addition, cases were also more often living in more populated areas than controls.
Fetal growth and other birth related characteristics
There was no association between birth weight or fetal growth, that is, appropriateness of birth weight or POBW (ESTELLE only) and any CBT or any of the ICCC-3 subtypes ( Table 2 ). The results did not differ by the mother's smoking status during the pregnancy (Results not shown).
There was no association seen with having a congenital malformation and CBT (Table 2 ) but there were insufficient data to investigate differences by types of congenital malformations (Supporting Information Table 2 ).
While no association was seen between birth by caesarean section and any CBT, the OR for astrocytoma was 1.5 (95% CI 1.0, 2.4) and 0.6 (95% CI 0.4, 1.0) for embryonal tumours (Table 2) .
Maternal gestational weight gain
There was no association with maternal prepregnancy BMI or appropriateness of maternal gestational weight gain (ESTELLE only; Supporting Information Table 3 ) or overall maternal gestational weight (Results not shown).
Folic acid, vitamins or minerals supplementation
Overall, the prevalence of any vitamin (including folic acid) or mineral supplementation in the three months before pregnancy was low in the ESTELLE study (5.3 and 7.8%, respectively, of case and control mothers; Table 3 ). Therefore, no analyses were done by CBT subtype. No association was seen with folic acid supplementation, or any vitamin (including folic acid) or mineral supplementation in the three months before pregnancy. There was no change when the analysis was restricted to substantiated folic acid, regardless of estimated daily dose. There was also no change when the analyses were stratified by the child's birth year group (results not tabulated).
The ORs for starting folic acid supplementation anytime during pregnancy was 1.6 (95% CI 1.2, 2.2), with little difference by whether it was started during the first trimester or later (Table 3) . Among those who started folic acid which was classed as substantiated during pregnancy, the OR was elevated among those who took <400 lg daily but not those who took 400 lg or more ( Table 3) . The results did not change when multiple births and children born following fertility treatments were excluded from these analyses.
Breastfeeding
Among children aged one year or more, no association was found with having being breastfed, or with duration of breastfeeding and CBT (Table 4) . Although not statistically significant, prolonged breastfeeding tended to be inversely p values comparing cases and controls of the combined studies, estimated using unconditional logistic regression model, adjusted for matching factors (sex and age). 3 These are only given for the study matching factors. 4 Age groups are based on the child's age at the censoring date. For cases, this was the date at diagnosis and for controls, it was the date of recruitment. Multivariate model also adjusted for birth order. 4 Also adjusted for birth order.
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POBW OR for every 1 SD (12.5%) increase. Multiple births and those with a gestational age <30 weeks or a POBW >200 were excluded from these analyses.
Cancer Epidemiology associated with astrocytomas and embryonal tumours. By contrast, a positive association was observed for other gliomas (OR 1.7, 95% CI 1.1, 2.9, p values for trend 0.02).
Maternal fertility and reproductive history
No association was found between any CBT and a history of difficulty in becoming pregnant in the index pregnancy, or the use of fertility treatment overall or by treatment type (Table 5) . Among the CBT subtypes, the OR for ependymoma following any difficulty in becoming pregnant was 1.9 (95% CI 1.1, 3.5).
No association was found with a history of having a miscarriage or therapeutic abortion at any time and CBT or any of its subtypes (Table 5 ) or prior to the index pregnancy (ESTELLE only, results not tabulated). When the analyses for miscarriage at any time were restricted to malignant cases (in an attempt to replicate the previously published ESCALE findings 33 ) the OR was 1.2 (95% CI 0.9, 1.5) and for malignant glioma 1.4 (95% CI 0.9, 2.2; results not tabulated) while the results for the other subtypes were unchanged.
Sensitivity analyses
Overall, the findings did not change when cases with nonmalignant tumours or children with NF (10 cases and two controls) were excluded from the analyses. Neither did they change when restricted to ESTELLE controls and cases (79.0% of all ESTELLE cases) with a landline.
Discussion
We did not find evidence to support our hypothesis of an association between CBT and fetal growth. In regards to maternal folic acid supplementation prior to conception, our findings are compatible with the hypothesis of an inverse association, although our findings did not reach statistical significance. The positive association seen between CBT and maternal low dose folic acid started during, but not before, pregnancy was unexpected. Finally, breastfeeding was also not associated with CBT, although for some subtypes (astrocytomas and embryonal tumours) the estimates for breastfeeding for at least six months tended to be less than unity. On the contrary, breastfeeding was positively associated with the ICCC-3 category other gliomas.
No association was found with having a congenital abnormality, birth by caesarean section, maternal difficulty in becoming pregnant or previous maternal miscarriage or therapeutic abortion. In addition, we did not replicate the Australian observation of an increased risk with inappropriate maternal GWG.
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Unlike previous recent studies conducted in the United States, 4,5,7 Scandinavia 8-10 and United Kingdom 5 which all used data linkage and an earlier meta-analysis of eight studies (five of which used data linkage), 41 we found no evidence to support our first hypothesis that the risk of CBT or any of its subtypes would be increased by high fetal growth or high birth weight. Nevertheless, our findings were similar to two case-control studies, that is, a multinational study 3 for birth weight and an Australian study 11 for birth weight, appropriateness of birth weight and POBW. It is noteworthy that the proportion of children with a birth weight of 4,000 g or more or a prolonged gestational age in our study population appear to have been different to others. About 9% of the controls had a birth weight of at least 4,000 g which was less than in previous papers with comparable data (between 12% and 20%). 5, [7] [8] [9] [10] Similarly, 3% of them were born after 41
weeks gestation compared 9% in others. 4, 9, 10 However, our data appear to be representative of the population as the French National Perinatal Surveys (ENPs) conducted between 1995 and 2010 reported that approximately 7% of babies had a birth weight of at least 4,000 g while few babies were born after 41 weeks gestation (<2%). 40 Nevertheless, it is important to question why recent findings in relation to birth weight and fetal growth appear to have varied by study design, with only case-control studies, which collected data by interview/questionnaire, finding no association. This type of study design may be prone to both non-differential measurement error and participation bias, which is not the case for the studies which used data linkage. There is some evidence that mothers recall birth weight and gestation accurately, 3 so measurement error may not be a major problem for these variables. While controls in our studies appeared to be representative of the French population, participation bias cannot be completely excluded. Conversely, it is worth noting that the evidence of an association between high birth weight and CBT from data linkage studies has come mainly from a few populations, mainly Scandinavia [8] [9] [10] and California, 4, 5, 7 so it is important to replicate these findings in other settings. Unconditional logistic regression model, adjusted for matching factors (sex and age) and study.
2 Unconditional polytomous regression model, adjusted for matching factors (sex and age) and study. 3 Children aged <1 year were excluded from these analyses.
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Bailey et al. Unconditional logistic regression, adjusted for matching factors (sex and age), and study unless otherwise stated.
2 Unconditional polytomous regression model, adjusted for matching factors (sex and age) and study unless otherwise stated. 3 The 1.0 (Referent) group are those who reported no difficulty in becoming pregnant. Model also adjusted for multiple births. 4 The 1.0 (Referent) group are those who reported never having a miscarriage, therapeutic or voluntary abortion.
We also found little evidence to support our second hypothesis that maternal folic preconceptional folic acid supplementation would be protective against CBT as has previously been reported. 12, 13 The first of these studies, conducted in Spain between 2004 and 2006 13 reported a reduction in risk with maternal folic supplementation of 400 mg/day prior to pregnancy, and within 21 or 36 days after conception, but not when these time periods were combined, while an Australian study, with cases diagnosed between 2005 and 2010, reported a reduction with folic acid supplementation in the month prior to and possibly during pregnancy, with some evidence of a dose response, especially before conception and during the first trimester. 12 The few others which have investigated folic acid separately from other vitamins focused mainly on during pregnancy, 16, 42, 43 not before, with two, one from Sweden 42 and an international collaboration 43 suggesting a risk reduction. However, it is hard to interpret the Swedish findings 42 as taking a multivitamin containing folic acid was classed as not taking folic acid and, for multivitamins, no association was seen. Finally, the third report from Norway using cases diagnosed between 1999 and 2010 found no association with folic acid supplementation at any time before (time period undefined) or during pregnancy. 16 We also did not find an inverse association with vitamin use in the periconceptional period as reported for medulloblastoma/PNET in two earlier reports from the United States Children's Oncology Group. 14, 15 The prevalence of folic acid supplementation in ESTELLE was low (8% of control mothers in preconception and 26% during pregnancy) compared to other studies conducted around the same time (e.g., 41% preconception and >80% within the last two trimesters in the Australian study 12 ). This difference is not surprising as the active promotion of periconceptional folic acid in France started in 2004 39 at least decade later than in Australia. 44 National data about perinatal folic acid supplementation in France were published for the first time in the 2010 ENP, 45 which reported that 14% women took folic acid before pregnancy and 40% during the pregnancy. Among the 122 ESTELLE controls born in 2010, the prevalence for the same time periods were 19% and 47%, respectively, which seems to suggest that our controls, at least for that birth year, were relatively representative. Similar to the 2010 ENP, 39 ESTELLE control mothers who took preconceptional folic acid were older, better educated, be more likely to be having their first child and to have used fertility treatments to become pregnant. We adjusted for maternal age and considered these other factors a priori as potential confounders. However, there could be other unmeasured factors related to folic acid use that affected our findings.
Our finding of an increased risk with folic acid supplementation commenced during pregnancy was unexpected and this could be a chance finding as the association was only seen among women who stated that they took less than the recommended dose of 400 mg. Finally, as most of these women used a product which contained other constituents as well as folic acid, we cannot interpret the finding as being specific to folic acid.
Our third hypothesis was that breastfeeding would be protective against CBT but we found no overall evidence to support this, which as well as replicating the previously published findings from ESCALE, 33 is also in line with previous literature from the United States, 46 Germany, 22 United Kingdom, 23 Sweden 24 and Australia. 19 The finding of an elevated OR for the ICCC-3 group of other gliomas is puzzling and to our knowledge, novel. We cannot think of a plausible biological explanation that could be specific to this heterogeneous group of CBT. In addition, the findings were not consistent across age-groups, so they could be due to chance.
The null finding for congenital malformations is consistent with a study which also used maternal report 11 as well as data linkage studies using birth, cancer and congenital malformation registers in Western Australia 47 and Texas, 28 but not with data linkage studies using birth and cancer registers in California 4 and Norway and Sweden 29 which reported an increased risk of CBT with central nervous system (CNS) malformations noted at birth. However, the small numbers in our study (four controls and no cases with a CNS malformation) precluded detailed analyses.
Our pooled analyses have several major strengths. First, as the ESTELLE study was designed to be pooled with the ESCALE study, the exposures had been uniformly defined, which facilitated the pooling process. In both studies, cases were selected from the population-based French National Registry of Childhood Cancers, which has a high degree of completeness and the overall participation rate among eligible cases was nearly 90%. However, as mothers whose children were receiving palliative care or had died were excluded from the study (11% of total cases), there is a risk of selection bias. If these children had been classed as eligible, the participation rate would be around 77%, which is around the same as reported in casecontrol studies in Australia (66%), 12 United States (69%) 46 and the large international SEARCH consortium (75%). 48 While only the Australian study specifically mentioned the exclusion of children who died before the families were invited to participate, 49 physicians declined to invite families for unstated medical reasons in all of these studies 12, 46, 48 and the similarity of participation rates suggests that even if not always a criterion for eligibility, severity of illness may play a role in the decision of parents to participate in case-control studies.
The participation rate was also high in controls (77%). Control selection was based on random generation of listed and unlisted telephone numbers, thus control households without a fixed telephone line were not accessible whereas cases (20% of all cases, according to ESTELLE data) could only be contacted by mobile telephone. Even so, the findings did not differ when the analyses for that study were repeated excluding these cases. While we do not have similar data for ESCALE, it is likely that fewer cases would have only had a mobile telephone since the study was conducted at least seven years earlier. While some of the characteristics of the controls varied between the studies, many of these differences are in line with trends seen in women giving birth in France as a whole between 1995 and 2010, that is, ESTELLE control mothers were older, better educated and more likely to breastfeed than those in ESCALE. 40 As all case-control studies there was the potential for recall bias. To minimize this, the interviews were conducted by trained interviewers, blinded to case-control status and neither they nor the mothers were aware of the study hypotheses. The child's personal health record, which was available for around 92% of cases and 96% of controls, contained information about many of the items of interest and mothers were asked to consult this in an effort to reduce non differential misclassification. However, it is possible that there was some misclassification in regards to the use of folic acid as more than half the women who said that they took it could not name the product. This contributed to reduce the power to detect a significant protective effect of preconceptional supplementation.
Despite having over 500 cases, the combined study was underpowered to investigate fully whether finding varied by CBT subtypes. While our results suggested some positive associations by subtypes, these findings could be unstable as they were often based on small numbers of exposed cases. Finally, as we performed many analyses, we cannot exclude the role of chance for these.
In conclusion, our findings from these pooled analyses using ESCALE and ESTELLE data, do not provide any evidence of an association between CBT and fetal growth, nor with breastfeeding. Any positive findings were restricted to subtypes of CBT, which need to be replicated in larger datasets. Finally, our findings provide little evidence of an inverse association, indicative of a protective role, with maternal preconceptional folic acid supplementation. Pooling data with other population-based studies may provide further insight.
